JP2017519015A - Ｏｔ−ｒ活性に関する疾患を治療するための方法に有用な結晶質の（３ｚ，５ｓ）−５−（ヒドロキシメチル）−１−［（２’−メチル−１，１’−ビフェニル−４−イル）カルボニル］ピロリジン−３−オン о−メチルオキシム - Google Patents

Ｏｔ−ｒ活性に関する疾患を治療するための方法に有用な結晶質の（３ｚ，５ｓ）−５−（ヒドロキシメチル）−１−［（２’−メチル−１，１’−ビフェニル−４−イル）カルボニル］ピロリジン−３−オン о−メチルオキシム Download PDF

Info

Publication number
JP2017519015A
JP2017519015A JP2016573776A JP2016573776A JP2017519015A JP 2017519015 A JP2017519015 A JP 2017519015A JP 2016573776 A JP2016573776 A JP 2016573776A JP 2016573776 A JP2016573776 A JP 2016573776A JP 2017519015 A JP2017519015 A JP 2017519015A
Authority
JP
Japan
Prior art keywords
methyl
biphenyl
carbonyl
hydroxymethyl
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016573776A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017519015A5 (OSRAM
Inventor
ショレ、アンドレ
Original Assignee
オブセヴァ エス．エー．
オブセヴァ エス．エー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オブセヴァ エス．エー．, オブセヴァ エス．エー． filed Critical オブセヴァ エス．エー．
Publication of JP2017519015A publication Critical patent/JP2017519015A/ja
Publication of JP2017519015A5 publication Critical patent/JP2017519015A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
JP2016573776A 2014-07-02 2015-06-10 Ｏｔ−ｒ活性に関する疾患を治療するための方法に有用な結晶質の（３ｚ，５ｓ）−５−（ヒドロキシメチル）−１−［（２’−メチル−１，１’−ビフェニル−４−イル）カルボニル］ピロリジン−３−オン о−メチルオキシム Pending JP2017519015A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462020076P 2014-07-02 2014-07-02
US62/020,076 2014-07-02
PCT/EP2015/062881 WO2016000920A1 (en) 2014-07-02 2015-06-10 Crystalline (3z,5s)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one o-methyloxime useful in methods of treating conditions related to the ot-r activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020186785A Division JP2021038236A (ja) 2014-07-02 2020-11-09 Ｏｔ−ｒ活性に関する疾患を治療するための方法に有用な結晶質の（３ｚ，５ｓ）−５−（ヒドロキシメチル）−１−［（２’−メチル−１，１’−ビフェニル−４−イル）カルボニル］ピロリジン−３−オン о−メチルオキシム

Publications (2)

Publication Number Publication Date
JP2017519015A true JP2017519015A (ja) 2017-07-13
JP2017519015A5 JP2017519015A5 (OSRAM) 2018-07-05

Family

ID=53434312

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016573776A Pending JP2017519015A (ja) 2014-07-02 2015-06-10 Ｏｔ−ｒ活性に関する疾患を治療するための方法に有用な結晶質の（３ｚ，５ｓ）−５−（ヒドロキシメチル）−１−［（２’−メチル−１，１’−ビフェニル−４−イル）カルボニル］ピロリジン−３−オン о−メチルオキシム
JP2020186785A Pending JP2021038236A (ja) 2014-07-02 2020-11-09 Ｏｔ−ｒ活性に関する疾患を治療するための方法に有用な結晶質の（３ｚ，５ｓ）−５−（ヒドロキシメチル）−１−［（２’−メチル−１，１’−ビフェニル−４−イル）カルボニル］ピロリジン−３−オン о−メチルオキシム
JP2022184804A Pending JP2023018037A (ja) 2014-07-02 2022-11-18 Ｏｔ－ｒ活性に関する疾患を治療するための方法に有用な結晶質の（３ｚ，５ｓ）－５－（ヒドロキシメチル）－１－［（２’－メチル－１，１’－ビフェニル－４－イル）カルボニル］ピロリジン－３－オン о－メチルオキシム
JP2024182585A Pending JP2025013885A (ja) 2014-07-02 2024-10-18 Ｏｔ－ｒ活性に関する疾患を治療するための方法に有用な結晶質の（３ｚ，５ｓ）－５－（ヒドロキシメチル）－１－［（２’－メチル－１，１’－ビフェニル－４－イル）カルボニル］ピロリジン－３－オン о－メチルオキシム

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020186785A Pending JP2021038236A (ja) 2014-07-02 2020-11-09 Ｏｔ−ｒ活性に関する疾患を治療するための方法に有用な結晶質の（３ｚ，５ｓ）−５−（ヒドロキシメチル）−１−［（２’−メチル−１，１’−ビフェニル−４−イル）カルボニル］ピロリジン−３−オン о−メチルオキシム
JP2022184804A Pending JP2023018037A (ja) 2014-07-02 2022-11-18 Ｏｔ－ｒ活性に関する疾患を治療するための方法に有用な結晶質の（３ｚ，５ｓ）－５－（ヒドロキシメチル）－１－［（２’－メチル－１，１’－ビフェニル－４－イル）カルボニル］ピロリジン－３－オン о－メチルオキシム
JP2024182585A Pending JP2025013885A (ja) 2014-07-02 2024-10-18 Ｏｔ－ｒ活性に関する疾患を治療するための方法に有用な結晶質の（３ｚ，５ｓ）－５－（ヒドロキシメチル）－１－［（２’－メチル－１，１’－ビフェニル－４－イル）カルボニル］ピロリジン－３－オン о－メチルオキシム

Country Status (13)

Country Link
US (2) US9718772B2 (OSRAM)
EP (2) EP3164384B1 (OSRAM)
JP (4) JP2017519015A (OSRAM)
KR (1) KR102470283B1 (OSRAM)
CN (3) CN114105850A (OSRAM)
AU (1) AU2015283133B2 (OSRAM)
CA (1) CA2953722C (OSRAM)
EA (2) EA031353B1 (OSRAM)
ES (1) ES2774789T3 (OSRAM)
IL (1) IL249652B (OSRAM)
MX (1) MX371068B (OSRAM)
UA (1) UA122210C2 (OSRAM)
WO (1) WO2016000920A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021042153A (ja) * 2019-09-10 2021-03-18 Ｊｆｅケミカル株式会社 パラターフェニルテトラカルボン酸およびパラターフェニルテトラカルボン酸二無水物の製造方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2845850A1 (en) 2013-09-10 2015-03-11 ObsEva S.A. Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists
EP2886107A1 (en) 2013-12-17 2015-06-24 ObsEva S.A. Oral formulations of pyrrolydine derivatives
MX371068B (es) 2014-07-02 2020-01-15 ObsEva SA ((3z,5s)-5-(hidroximetil)-1-[(2'-metil-1,1'-bifenil-4-il)carbonil ]pirrolidin-3-ona o-metiloxima cristalina y métodos de uso de la misma.
JP6933322B2 (ja) 2016-01-04 2021-09-08 メルク セローノ エス．エー． ヒドロキシプロピルチアゾリジンカルボキサミド誘導体のｌ−バリネート及びその塩形態、結晶多形
CA3031252A1 (en) 2016-07-21 2018-01-25 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
KR20220075340A (ko) * 2019-09-03 2022-06-08 옵스에파 에스에이 배아 착상을 촉진하고 유산을 예방하기 위한 옥시토신 길항제 투여 요법
AU2021218895A1 (en) 2020-02-10 2022-09-15 ObsEva S.A. Biomarkers for oxytocin receptor antagonist therapy
EP4313061A4 (en) * 2021-03-31 2025-03-05 The Board of Trustees of the Leland Stanford Junior University FORMULATIONS FOR PROLONGATION OF GESTATION AND FOR COMPLICATIONS OF MENSTRUATION OR GESTATION

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005533828A (ja) * 2002-07-05 2005-11-10 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ オキシトシン拮抗物質としてのピロリジン誘導体
JP6462030B2 (ja) * 2013-09-10 2019-01-30 オブセヴァ エス．エー． オキシトシン／バソプレッシンＶ１ａレセプターのアンタゴニストとしてのピロリジン誘導体を含有する医薬組成物

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU120988A (en) 1988-06-23 1990-06-30 Lek Tovarna Farmacevtskih Process for preparing new dispersion pills of cimetidine
YU183988A (en) 1988-09-30 1990-08-31 Lek Tovarna Farmacevtskih Process for preparing dispersion pills of dihydroergotoxine
US5089043A (en) 1989-11-09 1992-02-18 Shionogi & Co., Ltd. Heterocyclic oxy-phenoxyacetic acid derivatives and their use as herbicides
US5889001A (en) 1993-07-29 1999-03-30 American Cyanamid Company Tricyclic diazepine vasopressin antagonists and oxytocin antagonists
JP3534903B2 (ja) 1995-06-09 2004-06-07 鐘淵化学工業株式会社 １−［３−クロロ−（２ｓ）−メチルプロピオニル］−ピロリジン−（２ｓ）−カルボン酸の製造方法
GB9603699D0 (en) 1996-02-21 1996-04-17 Boots Co Plc Therapeutic composition
US6696484B2 (en) 1997-10-31 2004-02-24 University Of Chicago Office Of Technology And Intellectual Property Method and compositions for regulation of 5-alpha reductase activity
US6329418B1 (en) 1998-04-14 2001-12-11 The Procter & Gamble Company Substituted pyrrolidine hydroxamate metalloprotease inhibitors
JP4040878B2 (ja) 1999-12-09 2008-01-30 レキット ベンキーザー ヘルスケア （ユーケイ） リミテッド 治療薬
CA2401137A1 (en) 2000-03-27 2001-10-11 Applied Research Systems Ars Holding N.V. Pharmaceutically active pyrrolidine derivatives as bax inhibitors
JP2003528854A (ja) 2000-03-27 2003-09-30 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 医薬として活性なピロリジン誘導体
TW536751B (en) 2000-07-14 2003-06-11 Nitto Denko Corp Cleaning sheet, conveying member using the same, and substrate processing equipment cleaning method using them
DE60226431D1 (de) 2001-03-20 2008-06-19 Serono Lab Pyrrolidinesterderivate mit oxytocinmodulierender wirkung
KR200245627Y1 (ko) * 2001-05-15 2001-10-15 김병두 전기 가열부재가 부착된 냄비
AU2002319237B2 (en) 2001-06-18 2008-01-03 Merck Serono Sa Pyrrolidine oxadiazole- and thiadiazole oxime derivatives being oxytocin receptor antagonists
JP2003192582A (ja) 2001-12-12 2003-07-09 Merck Patent Gmbh ナプロキセンナトリウムを含む速放性錠剤
ATE449067T1 (de) 2003-02-27 2009-12-15 Merck Serono Sa Pyrrolidin-derivate als oxytocin antagonisten
ES2296137T3 (es) 2004-02-26 2008-04-16 Laboratoires Serono Sa Metodo para preparar pirrolidin-oximas.
GB2411355B (en) 2004-02-27 2006-02-22 Niche Generics Ltd Pharmaceutical composition
CA2605923C (en) 2005-05-10 2012-07-24 Ferring International Center Sa. Use of antagonists of oxytocin and/or vasopressin
JP2008189732A (ja) 2007-02-01 2008-08-21 Fujifilm Corp セルロースアシレート組成物、セルロースアシレートフィルム、光学補償シート、偏光板および液晶表示装置
PT2572705T (pt) 2007-10-01 2017-11-08 Lesvi Laboratorios Sl Comprimidos orodispersíveis
US9201077B2 (en) 2009-07-27 2015-12-01 Colorado State University Research Foundation Direct enzyme immunoassay for measurement of serum progesterone levels
CA2892000A1 (en) 2012-11-26 2014-05-30 Piotr Pierzynski Method and system for diagnosing uterine contraction levels using image analysis
EP2886107A1 (en) 2013-12-17 2015-06-24 ObsEva S.A. Oral formulations of pyrrolydine derivatives
MX371068B (es) 2014-07-02 2020-01-15 ObsEva SA ((3z,5s)-5-(hidroximetil)-1-[(2'-metil-1,1'-bifenil-4-il)carbonil ]pirrolidin-3-ona o-metiloxima cristalina y métodos de uso de la misma.
ES2716862T3 (es) 2014-12-22 2019-06-17 Ferring Bv Terapia con antagonistas del receptor de oxitocina en la fase lútea para la implantación y embarazo en mujeres que se someten a tecnologías de reproducción asistida

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005533828A (ja) * 2002-07-05 2005-11-10 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ オキシトシン拮抗物質としてのピロリジン誘導体
JP6462030B2 (ja) * 2013-09-10 2019-01-30 オブセヴァ エス．エー． オキシトシン／バソプレッシンＶ１ａレセプターのアンタゴニストとしてのピロリジン誘導体を含有する医薬組成物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
社団法人 日本化学会, 実験化学講座１ 基本操作Ｉ, vol. 第４版, JPN6018001753, 5 November 1990 (1990-11-05), pages 184 - 186, ISSN: 0003975180 *
芦澤 一英、他, 医薬品の多形現象と晶析の科学, JPN7015003233, 20 September 2002 (2002-09-20), pages 305 - 317, ISSN: 0003975181 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021042153A (ja) * 2019-09-10 2021-03-18 Ｊｆｅケミカル株式会社 パラターフェニルテトラカルボン酸およびパラターフェニルテトラカルボン酸二無水物の製造方法
JP7083793B2 (ja) 2019-09-10 2022-06-13 Ｊｆｅケミカル株式会社 パラターフェニルテトラカルボン酸およびパラターフェニルテトラカルボン酸二無水物の製造方法

Also Published As

Publication number Publication date
CN114105850A (zh) 2022-03-01
EP3164384A1 (en) 2017-05-10
JP2023018037A (ja) 2023-02-07
CA2953722A1 (en) 2016-01-07
JP2021038236A (ja) 2021-03-11
AU2015283133A1 (en) 2017-02-16
US20170320822A1 (en) 2017-11-09
IL249652A0 (en) 2017-02-28
IL249652B (en) 2021-09-30
MX371068B (es) 2020-01-15
CN106795110A (zh) 2017-05-31
EA031353B1 (ru) 2018-12-28
US20160002160A1 (en) 2016-01-07
ES2774789T3 (es) 2020-07-22
EA201891873A1 (ru) 2019-04-30
AU2015283133B2 (en) 2019-05-16
CN114105851A (zh) 2022-03-01
KR102470283B1 (ko) 2022-11-23
UA122210C2 (uk) 2020-10-12
EP3753921A1 (en) 2020-12-23
JP2025013885A (ja) 2025-01-28
WO2016000920A1 (en) 2016-01-07
KR20170023961A (ko) 2017-03-06
EA201790080A1 (ru) 2017-06-30
CA2953722C (en) 2022-09-13
US9718772B2 (en) 2017-08-01
EP3164384B1 (en) 2019-12-04
US10752583B2 (en) 2020-08-25
MX2016016751A (es) 2017-08-08

Similar Documents

Publication Publication Date Title
JP2023018037A (ja) Ｏｔ－ｒ活性に関する疾患を治療するための方法に有用な結晶質の（３ｚ，５ｓ）－５－（ヒドロキシメチル）－１－［（２’－メチル－１，１’－ビフェニル－４－イル）カルボニル］ピロリジン－３－オン о－メチルオキシム
JP6462030B2 (ja) オキシトシン／バソプレッシンＶ１ａレセプターのアンタゴニストとしてのピロリジン誘導体を含有する医薬組成物
HK40039130A (en) Crystalline (3z,5s)-5-(hydroxymethyl)-1-[(2’-methyl-1,1’-biphenyl-4-yl)carbonyl]pyrrolidin-3-one o-methyloxime useful in methods of treating conditions related to the ot-r activity
BR112016030894B1 (pt) Composto cristalino, composição farmacêutica e método para preparar um composto cristalino
HK1231866A1 (en) Crystalline (3z,5s)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one o-methyloxime useful in methods of treating conditions related to the ot-r activity
HK1231866B (en) Crystalline (3z,5s)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one o-methyloxime useful in methods of treating conditions related to the ot-r activity
EA049934B1 (ru) ПРОИЗВОДНЫЕ ПИРРОЛИДИНА В КАЧЕСТВЕ АНТАГОНИСТОВ РЕЦЕПТОРОВ ОКСИТОЦИНА/ВАЗОПРЕССИНА V1a

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180523

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180523

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190212

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190513

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190827

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200227

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200707